FOLactis
Pleural Effusion, Malignant
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Pleural Effusion, Malignant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate Novartis Pharmaceuticals | Phase 4 | BB |
Nivolumab Kidney Cancer Research Bureau | Phase 2 | B |
Docetaxel Asan Medical Center | Phase 2 | B |
Rso-021 RS Oncology LLC | Phase 1/2 | CCC |
(+)-VINCRISTINE Institut Curie | Phase 1 | CC |
View all 9 →
Same molecule, other indications
FOLactis is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →